Research Committee

The NANETS Research Committee is dedicated to supporting new and dynamic neuroendocrine research. 

NANETS supports neuroendocrine research in a variety of ways:

Awards and Scholarships
New research efforts are supported through our Awards and Scholarships. Granting research funds to researchers and clinicians fosters inquiry and creates mentorship opportunities for upcoming physicians in the field.

Keeping Informed
NANETS strives to keep its members and site visitors informed of scientific developments related to neuroendocrine tumors. We encourage such developments by supporting joint research efforts and protocols, and assisting members in developing cooperative projects.

Please click here to contact us if you wish to be a part of this committe, or have ideas to share. If you want your clinical trial or study posted, please click here

Practice Changing Phase III Trials Presented at 2015 NANETS Symposium

The results of three recent, practice-changing phase III clinical trials were presented for the first time in North America at the NANETS symposium which included: (1) TELESTAR (randomized phase III trial of Telotristat vs. Placebo in patients with carcinoid syndrome), (2) NETTER-1 (randomized phase III trial of 177-Lu-DOTATATE vs.

NET Studies Presented at the 2015 ASCO Annual Conference

Recently, two multi-institutional cooperative group trials looked at synergistic uses with common related therapies, moving toward the goal of uncovering new standards of care for this rare disease.

NET SPORE Funding Opportunities

Deadline Approaching for Three Funding Opportunities from the University of Iowa

University of Iowa’s Neuroendocrine Tumor Specialized Program of Research Excellence (NET SPORE) has three funding opportunities available. The awards are for the NET SPORE Developmental Research Program, and the NET SPORE Career Enhancement Program. The first deadline for letters of concept is August 3, 2015.

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors

NovartisOn May 21, 2015 Novartis announced that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.